Ablynx Adds Sanofi To Its List Of Big Pharma Partners
Sanofi is the latest big pharma, following on from Merck & Co., AbbVie and others, to team up with Belgian Nanobody drug developer Ablynx.
You may also be interested in...
Sanofi's €3.9bn acquisition of Ablynx will allow the French big pharma to build up its rare blood disorder pipeline and bring in complementary programs in areas like respiratory infections.
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.